Objective: To establish an HPLC-principal component self-compare with correction factor method for quantification of two related substances (N-deacetyllappaconitine and ranaconitine) in lappaconitine hydrobromide injection. Methods: The analysis was performed on a Kromasil 300-5-C18 (250 mm×4.6 mm,5 μm) column with a mobile phase composed of 0.04 mol·L-1 potassium dihydrogen phosphate solution, methanol and acetonitrile (68∶17∶15). The detection wavelength was 252 nm, the flow rate was 0.8 mL·min-1, the column temperature was 37 ℃, and the injection volume was 10 μL. The slope of linear equation was used to determine the relative correction factor between the two impurities and lappaconitine hydrobromide. The relative retention time was used to determine the position of related substances. The contents of two impurities in 25 batches of lappaconitine hydrobromide injection produced by four pharmaceutical companies were determined and compared with the results of the external standard method. Results: Lappaconitine hydrobromide and the impurities were separated well by this method. The relative retention time of N-deacetyllappaconitine and ranaconitine were 1.20 and 1.39, and the correction factors were 1.23 and 0.94, respectively. Lappaconitine hydrobromide, N-deacetyllappaconitine and ranaconitine showed good linearity in the mass concentration ranges of 0.951 7-38.07 μg·mL-1, 1.047-41.87 μg·mL-1 and 1.001-40.02 μg·mL-1 with r=1.000, respectively. The average recovery rates of lappaconitine hydrobromide, N-deacetyllappaconitine and ranaconitine were 100.2%, 100.5% and 100.5% respectively, with RSD less than 2.0%. The limits of detection (LOD) of lappaconitine hydrobromide, N-deacetyllappaconitine and ranaconitine were 0.095, 0.10, 0.10 μg·mL-1 and the limits of quantitation (LOQ) were 0.32, 0.35 and 0.33 μg·mL-1, respectively. The content of N-deacetyllappaconitine in 25 batches of lappaconitine hydrobromide injection was in the range of 0.31%-0.82% and the content of ranaconitine was in the range of 0%-0.09%. It was consistent with the determination result of the external standard method. Conclusion: The method is proved to be simple, rapid, and accurate for the determination of related substances in lappaconitine hydrobromide injection.
XU Shu-juan
,
ZHANG Lei
,
MA Shu-feng
,
FU Xia
,
LU Na
,
WU Chuan-li
. Determination of two related substances in lappaconitine hydrobromide injection by HPLC-principal component self-compare with correction factor*[J]. Chinese Journal of Pharmaceutical Analysis, 2024
, 44(11)
: 1967
-1974
.
DOI: 10.16155/j.0254-1793.2024-0149
[1] 霍艳飞,田月洁,许莉莉,等. 535例氢溴酸高乌甲素制剂新的和严重的药品不良反应报告分析[J]. 中国药物警戒,2023,20(8):921
HUO YF, TIAN YJ, XU LL, et al. 535 reports of new and serious adverse drug reactions caused by preparations of lappaconitine hydrobromide [J]. Chin J Pharmacovigil, 2023, 20(8):921
[2] 王文丽,张晓明,田向斌,等. 氢溴酸高乌甲素的生物药剂学分类属性研究[J]. 药物分析杂志,2023,43(9):1451
WANG WL, ZHANG XM, TIAN XB, et al. Study on attribute of biopharmaceutics classification system of lappaconitine hydrobromide [J]. Chin J Pharm Anal, 2023, 43(9):1451
[3] 张尹,高召兵,辛晓明,等. 高乌甲素药理活性的研究进展[J]. 生命科学,2021,33(9): 1089
ZHANG Y, GAO ZB, XIN XM, et al. Research progress on the pharmacological activity of lappaconitine [J]. Chin Bull Lif Sci, 2021, 33(9): 1089
[4] 魏华波,张宝华,谭兵,等.氢溴酸高乌甲素的药理作用及临床应用研究进展[J]. 重庆医学,2014,43 (20):2660
WEI HB, ZHANG BH, TIAN B, et al. Advances in pharmacological action and clinical application of lappaconitine hydrobromide [J]. Chongqing Med, 2014, 43(20): 2660
[5] 李婉茹. 氢溴酸高乌甲素长效注射剂的制备及体内外镇痛作用评价[D]. 上海:上海中医药大学,2020
LI WR. Preparation and Analgesic Effect Evaluation of Lappaconitine Hydrobromide Long-Acting Injection In Vitro and In Vivo [D]. Shanghai: Shanghai University of Traditional Chinese Medicine, 2020
[6] 黄维艳, 欧珊. 氢溴酸高乌甲素在镇痛的研究进展[J]. 中华卫生应急电子杂志,2016,2(6):377
HUANG WY, OU S. Research progress of lappaconitine hydrobromide in analgesia [J]. Chin J Hyg Rescue (Eletron Ed), 2016, 2(6): 377
[7] 卫生部药品标准. 二部.第五册[S]. 1996: 54
Drug Specifications Promulgated by the Ministry of Public Health. PR China. Part 2. Vol 5 [S]. 1996: 54
[8] YBH16992004国家食品药品监督管理局标准—氢溴酸高乌甲素注射液[S]. 2004
YBH16992004 Quality Standard of the State Food and Drug Administration. Lappaconitine Hydrobromide Injection [S]. 2004
[9] YBH22682005国家食品药品监督管理局标准—氢溴酸高乌甲素注射液[S]. 2005
YBH22682005 Quality Standard of the State Food and Drug Administration. Lappaconitine Hydrobromide Injection[S]. 2005
[10] 陈露,蔡姗英,鲁秋红. LC-Q-TOF/MS方法分析氢溴酸高乌甲素及其注射剂中有关物质[J]. 药物分析杂志,2013,33(12):2129
CHEN L, CAI SY, LU QH. LC-Q-TOF/MS analysis of related substances in lappaconite hydrobromide and its injection [J]. Chin J Pharm Anal, 2013, 33(12):2129
[11] 刘松东,邱健珉,王兰兰,等. 1101例氢溴酸高乌甲素不良反应分析[J]. 中国药物警戒,2018,15(11): 686
LIU SD, QIU JM, WANG LL, et al. Analysis of 1101 cases of adverse drug reactions induced by lappaconitine hydrobromide [J]. Chin J Pharmacovigil, 2018, 15(11): 686
[12] 李霞,田月洁,霍艳飞,等. 氢溴酸高乌甲素注射剂药品不良反应及风险因素分析[J]. 食品与药品,2022,24(5):442
LI X, TIAN YJ, HUO YF, et al. Analysis of adverse drug reaction and risk factors induced by lappaconitine hydrobromide injection [J]. Food Drug, 2022, 24(5): 442
[13] 陈露,蔡姗英,鲁秋红. HPLC法测定氢溴酸高乌甲素的有关物质[J]. 广东药学院学报,2013,29(5): 518
CHEN L, CAI SY, LU QH. HPLC determination of related substances in lappaconite hydrobromide [J]. J Guangdong Pharm Univ, 2013 (5): 518
[14] 刘朝霞,黄海伟,张启明,等. HPLC法测定氢溴酸高乌甲素注射液有关物质的研究[J]. 药物分析杂志,2009,29(5):795
LIU ZX, HUANG HW, ZHANG QM, et al. HPLC determination of related substance of lappaconite hydrobromide injection [J]. Chin J Pharm Anal, 2009 (5): 795
[15] 王践玲,袁才英,于武高,等. 氢溴酸高乌甲素质量标准研究[J]. 内蒙古中医药,2013,32(13):109
WANG JL, YUAN CY, YU WG, et al. Quality standard for lappaconitine hydrobromide [J]. Inner Mongolia J Tradit Chin Med, 2013, 32(13): 109
[16] 肖亭,王晨,姚尚辰,等. HPLC 校正因子法在药物分析中的应用[J]. 药学学报,2020,55(12):2854
XIAO T, WANG C, YAO SC, et al. Application of an HPLC correction factor method in pharmaceutical analysis [J]. Acta Pharm Sin, 2020, 55(12): 2854
